Pharma executives slam Europe's patent regime, while praising the US approach
Europe significantly lags the United States in terms of its regulatory and IP regimes for companies in the life sciences industries, according to respondents to a survey published today by Marks & Clerk.
The EU's perceived hostility to the way in…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.